Third-party litigation funding has been a source of controversy in the U.S. over the past decade, but the practice drew little national scrutiny up to now.
In an effort to shore up its position in a rapidly developing market for brain-computer interface (BCI) technologies, Onward Medical NV signed an exclusive license with France’s CEA-Clinatec to use ...
This summer’s IPO by Artiva Biotherapeutics Inc. highlighted early stage efforts with natural killer cells in autoimmune disease, where a handful of companies are advancing programs. The firm raised ...
Co. Ltd. and affiliated organizations have reported the design and preclinical characterization of novel erythrocytes conjugated to major histocompatibility complex (MHC) class I (MHC-I) protein, ...
China’s National Medical Products Administration has given the thumbs up to Junshi Biosciences Co. Ltd.’s NDA for ongericimab, a recombinant humanized anti-PCSK9 monoclonal antibody, marking the third ...
Copyright ©2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...
Copyright ©2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Manage cookie preferences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback